• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.

作者信息

Rowland Andrew, Dias Mafalda M, Wiese Michael D, Kichenadasse Ganessan, McKinnon Ross A, Karapetis Christos S, Sorich Michael J

机构信息

Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.

Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide 5042, South Australia, Australia.

出版信息

Br J Cancer. 2015 Dec 1;113(11):1635. doi: 10.1038/bjc.2015.325. Epub 2015 Sep 10.

DOI:10.1038/bjc.2015.325
PMID:26355231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4705877/
Abstract
摘要

相似文献

1
Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.回复：对“BRAF突变作为RAS野生型转移性结直肠癌抗表皮生长因子受体单克隆抗体治疗获益预测生物标志物的Meta分析”的评论
Br J Cancer. 2015 Dec 1;113(11):1635. doi: 10.1038/bjc.2015.325. Epub 2015 Sep 10.
2
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.BRAF突变作为RAS野生型转移性结直肠癌抗表皮生长因子受体单克隆抗体治疗获益预测生物标志物的Meta分析。
Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19.
3
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.KRAS、NRAS、BRAF、PIK3CA和PTEN对转移性结直肠癌抗表皮生长因子受体治疗的预测价值：一项系统评价和荟萃分析。
Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25.
4
Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.抗表皮生长因子受体单克隆抗体治疗转移性结直肠癌患者中 BRAF 突变的预测和预后作用：一项荟萃分析。
J Dig Dis. 2013 Aug;14(8):409-16. doi: 10.1111/1751-2980.12063.
5
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.表皮生长因子受体（EGFR）基因拷贝数可预测RAS野生型及RAS/ BRAF/PIK3CA野生型转移性结直肠癌患者对抗表皮生长因子受体治疗的反应。
Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.
6
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.BRAF突变在接受西妥昔单抗和帕尼单抗治疗的晚期结直肠癌患者中的预测作用：一项荟萃分析。
Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9.
7
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.转移性结直肠癌抗表皮生长因子受体治疗中的预后和预测生物标志物
World J Gastroenterol. 2016 Aug 14;22(30):6944-54. doi: 10.3748/wjg.v22.i30.6944.
8
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.分析PTEN、BRAF和EGFR状态以确定野生型KRAS转移性结肠癌患者从西妥昔单抗治疗中获益的情况。
J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.
9
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.抗表皮生长因子受体单克隆抗体治疗 KRAS 野生型转移性结直肠癌患者结局的有前途的生物标志物：系统评价与荟萃分析。
Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13.
10
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.结直肠癌患者综合治疗中的预测和预后因素。
Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

引用本文的文献

1
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?社区环境中的BRAF突变检测与转移性结直肠癌：是否迫切需要更多教育？
Mol Diagn Ther. 2016 Feb;20(1):75-82. doi: 10.1007/s40291-015-0179-7.

本文引用的文献

1
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.BRAF突变作为RAS野生型转移性结直肠癌抗表皮生长因子受体单克隆抗体治疗获益预测生物标志物的Meta分析。
Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19.
2
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.BRAF突变在接受西妥昔单抗和帕尼单抗治疗的晚期结直肠癌患者中的预测作用：一项荟萃分析。
Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9.
3
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.延长 RAS 突变和抗 EGFR 单克隆抗体在转移性结直肠癌中的生存获益：随机对照试验的荟萃分析。
Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12.
4
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.评估和报告临床试验中治疗效果的异质性：建议。
Trials. 2010 Aug 12;11:85. doi: 10.1186/1745-6215-11-85.
5
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses.亚组效应可信吗？更新评估亚组分析可信度的标准。
BMJ. 2010 Mar 30;340:c117. doi: 10.1136/bmj.c117.
6
Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.治疗个体2. 随机对照试验中的亚组分析：重要性、指征及解读
Lancet. 2005;365(9454):176-86. doi: 10.1016/S0140-6736(05)17709-5.
7
Statistics notes. Interaction 2: Compare effect sizes not P values.统计学笔记。交互作用2：比较效应量而非P值。
BMJ. 1996 Sep 28;313(7060):808. doi: 10.1136/bmj.313.7060.808.
8
Statistics notes. Interaction 1: Heterogeneity of effects.统计学注释。交互作用1：效应的异质性。
BMJ. 1996 Aug 24;313(7055):486. doi: 10.1136/bmj.313.7055.486.